To supplement our consolidated financial statements presented in accordance with IFRS, we use adjusted net (loss)/profit (non-IFRS measure) as additional financial measures, which are not required by, or presented in accordance with IFRS.
Summary · 第 14 页
We believe that this non-IFRS measure facilitate comparisons of operating performance from year to year and company to company by eliminating potential impacts of certain items, such as share-based payments for employees, interest expense on financial liabilities to investors, loss on convertible redeemable preferred shares and listing expenses.
Summary · 第 14 页
Our adjusted loss (non-IFRS measure) decreased from RMB379.4 million in 2022 to RMB205.7 million in 2023, which was primarily attributable to the increase of gross profit from RMB273.5 million to RMB434.6 million.
金叶国际集团有限公司GOLDEN LEAF INTERNATIONAL GROUP LIMITED08549.HK
经调整净利润（非HKFRS计量）
To supplement our consolidated financial statements which are presented in accordance with HKFRSs, we also presented the adjusted net profit (Non-HKFRS measure) and adjusted net profit margin (Non-HKFRS measure) as additional financial measures, which are not required by, or presented in accordance with HKFRSs.
Summary · 第 12 页
Listing expenses are mainly expenses related to the Listing and are added back because they were incurred only for the purposes of the Listing.
Summary · 第 12 页
The use of non-HKFRS financial measures has limitations as an analytical tool, and investors should not consider these in isolation from, or as a substitute for, or superior to, analysis of our results of operations or financial conditions as reported in accordance with HKFRSs.
We define adjusted net loss (a non-IFRS measure) as loss for the year adjusted for (i) equity-settled share-based payment expenses, (ii) listing expenses, and (iii) interest expenses on financial instruments issued to investors.
Summary · 第 16 页
In 2022, 2023 and 2024, our adjusted net loss (a non-IFRS measure) was RMB142.6 million, RMB189.8 million and RMB217.6 million, respectively.
Summary · 第 16 页
Our adjusted net loss margin (a non-IFRS measure), representing adjusted net loss (a non-IFRS measure) as a percentage of revenue, was 39.6%, 40.9% and 34.2% in 2022, 2023 and 2024, respectively, showing a decreasing trend primarily as a result of a decrease of operating expenses as a percentage of revenue and an increase in our gross profit margin as we began realizing economies of scale.
We define adjusted profit/(loss) for the year/period (a non-IFRS measure) as profit/(loss) for the year/period adjusted for fair value changes on convertible redeemable preferred shares (a non-cash item), listing expenses and share-based compensations (a non-cash item).
Summary · 第 14 页
In particular, convertible redeemable preferred shares will be reclassified from liabilities to equity as a result of the conversion of convertible redeemable preferred shares into Ordinary Shares upon Listing.
We define adjusted net loss (non-IFRS measure) as profit/(loss) for the year/period excluding the effects of fair value changes on convertible redeemable preferred shares, share-based payments and listing expenses.
Summary · 第 9 页
Our adjusted net loss (non-IFRS measure) reduced from RMB118.7 million in 2022 to RMB115.6 million in 2023 and from RMB30.7 million for the three months ended March 31, 2023 to RMB24.2 million for the three months ended March 31, 2024, and our adjusted net loss margin (non-IFRS measure) reduced from 10.3% in 2022 to 8.7% in 2023 and 7.1% for the three months ended March 31, 2024, respectively.
We define adjusted net loss (non-IFRS measure) as net loss for the year, adjusted by adding share-based payment expenses, listing expenses, and fair value changes of financial liabilities at FVTPL relating to shares with preferential rights issued by us, which are non-cash in nature.
Summary · 第 13 页
The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for an analysis of, our results of operations or financial condition as reported under IFRSs.
For 2020, 2021 and 2022 and the five months ended 31 May 2022 and 2023, we recorded gains arising from changes in fair value of biological assets of RMB1,295.7 million, losses arising from changes in fair value of biological assets of RMB2,753.5 million, gains arising from changes in fair value of biological assets of RMB304.8 million, losses arising from changes in fair value of biological assets of RMB419.3 million and losses arising from changes in fair value of biological assets of RMB1,202.4 million, respectively.
Financial Information · 第 358 页
The fair value measurements of biological assets fall into level 3 of the fair value hierarchy.
Financial Information · 第 345 页
Therefore, the fair value of our biological assets could be affected by, among other things, the accuracy of such assumptions, and any changes in the estimates may affect the fair value of our biological assets significantly.
Listing expenses are the expenses relating to the Global Offering. Share-based compensation is non-cash expenses arising from granting restricted share award and options to senior management and employees.
Summary · 第 17 页
The use of these non-IFRS measures has limitations as an analytical tool, and you should not consider them in isolation from, as a substitute for, analysis of, or superior to, our results of operations or financial condition as reported under IFRSs.